Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Ming Quan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0828-1324; OpenAlex author ID A5045897433. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 4 papers · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 16

  1. Stiripentol induces ER stress and pyroptosis in pancreatic cancer cells under metabolic stress by dysregulating SFAs/UFAs homeostasis. Last author DOI 10.1007/s13402-026-01205-6↗
  2. LPA released from dying cancer cells after chemotherapy inactivates Hippo signaling and promotes pancreatic cancer cell repopulation. Last author DOI 10.1007/s13402-025-01038-9↗
  3. Publisher Correction to: LPA released from dying cancer cells after chemotherapy inactivates Hippo signaling and promotes pancreatic cancer cell repopulation. Last author DOI 10.1007/s13402-025-01047-8↗
  4. Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib. Co-author DOI 10.1186/s12943-024-01965-5↗
  5. Chemotherapeutic drugs-induced pyroptosis mediated by gasdermin E promotes the progression and chemoresistance of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2023.216206↗
  6. Screening and discrimination of optimal prognostic genes for pancreatic cancer based on a prognostic prediction model. Co-author DOI 10.1093/g3journal/jkab296↗
  7. RNA-binding protein Musashi2 regulates Hippo signaling via SAV1 and MOB1 in pancreatic cancer. Co-author DOI 10.1007/s12032-020-01384-8↗
  8. A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism. First author DOI 10.1038/s41388-019-1051-8↗
  9. Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression. Co-author DOI 10.1186/s13046-019-1489-0↗
  10. The FOXM1/ATX signaling contributes to pancreatic cancer development. Co-author PMID 32913521↗
  11. MST1 Suppresses Pancreatic Cancer Progression via ROS-Induced Pyroptosis. Last author DOI 10.1158/1541-7786.mcr-18-0910↗
  12. The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-16-1064↗
  13. The critical role and potential target of the autotaxin/lysophosphatidate axis in pancreatic cancer. Co-author DOI 10.1177/1010428317694544↗
  14. HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes. Co-author DOI 10.1038/onc.2016.14↗
  15. Suppressed expression of LDHB promotes pancreatic cancer progression via inducing glycolytic phenotype. First author DOI 10.1007/s12032-015-0589-8↗
  16. Hippo transducer TAZ promotes epithelial mesenchymal transition and supports pancreatic cancer progression. Last author DOI 10.18632/oncotarget.5772↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jiujie Cui · 11 shared papers, 2015–2024 · strength 1.09
  2. Jie Ding · 2 shared papers, 2025–2026 · strength 0.62
  3. Yuzhi Liu · 2 shared papers, 2025 · strength 0.61
  4. Yong Gao · 5 shared papers, 2015–2021 · strength 0.50
  5. Haiyan Yang · 4 shared papers, 2019–2024 · strength 0.50
  6. Liwei Wang · 4 shared papers, 2019–2023 · strength 0.47
  7. Dacheng Xie · 4 shared papers, 2015–2020 · strength 0.38
  8. Feng Jiao · 4 shared papers, 2015–2020 · strength 0.37
  9. Xiaofei Zhang · 2 shared papers, 2023–2024 · strength 0.34
  10. Tiebo Mao · 2 shared papers, 2023–2024 · strength 0.34
  11. Weiyu Ge · 2 shared papers, 2023–2024 · strength 0.34
  12. Zhiqin Chen · 2 shared papers, 2020–2021 · strength 0.27
  13. Keping Xie · 3 shared papers, 2015–2020 · strength 0.23
  14. Lei Wang · 1 shared paper, 2024 · strength 0.18
  15. Liang Wang · 3 shared papers, 2015–2017 · strength 0.17
  16. Shengbai Xue · 1 shared paper, 2023 · strength 0.16
  17. Shumin Li · 1 shared paper, 2023 · strength 0.16
  18. Li Li · 1 shared paper, 2020 · strength 0.15
  19. Yong Gao · 1 shared paper, 2020 · strength 0.15
  20. Jiong Hu · 1 shared paper, 2020 · strength 0.12
  21. Sushovan Guha · 1 shared paper, 2020 · strength 0.12
  22. Qian Huang · 1 shared paper, 2017 · strength 0.10
  23. Qingyong Ma · 1 shared paper, 2017 · strength 0.07
  24. Daoyan Wei · 1 shared paper, 2017 · strength 0.07
  25. Kun Guo · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.